FYERS
Home
/
Stocks
/
Results
/
Sai Parenteral's Results

Sai Parenteral's Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
--58%134%
--56%-1%
----
13%13%13%5%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
SAIPARENT
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,769.9₹424202 Cr38.688.2958.23₹11479 Cr
10,064₹264141 Cr90.334.04128.41₹2568 Cr
4,650₹174402 Cr82.1114.04106.21₹2163 Cr
2,323₹126811 Cr94.648.1733.94₹889 Cr
1,240.6₹123685 Cr27.419.4262.53₹5040 Cr
1,368.3₹111868 Cr39.9511.0859.2₹4196 Cr
1,396.9₹111650 Cr38.5410.8652.6₹3879 Cr
2,475₹102196 Cr45.5717.2376.26₹1913 Cr
1,694.5₹96951 Cr26.1117.9596.84₹3505 Cr
2,015.9₹91301 Cr16.5130.95154.35₹5333 Cr
469.25₹2123 Cr128.662.387.55₹17 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Sep 2026Jun 2026Mar 2026Sep 2025Jun 2025
₹195 Cr₹179 Cr₹198 Cr₹54 Cr₹33 Cr
₹4 Cr₹4 Cr₹3 Cr₹1 Cr₹1 Cr
₹199 Cr₹182 Cr₹201 Cr₹55 Cr₹35 Cr
₹180 Cr₹163 Cr₹180 Cr₹44 Cr₹30 Cr
₹44 Cr₹27 Cr₹29 Cr₹13 Cr₹6 Cr
₹9 Cr₹9 Cr₹8 Cr₹2 Cr₹2 Cr
₹10 Cr₹10 Cr₹12 Cr₹9 Cr₹2 Cr
₹11 Cr₹8 Cr₹13 Cr₹6 Cr₹1 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023
————
₹22 Cr₹13 Cr₹13 Cr₹7 Cr
₹469 Cr₹80 Cr₹61 Cr₹24 Cr
₹469 Cr₹80 Cr₹61 Cr₹24 Cr
₹491 Cr₹94 Cr₹75 Cr₹31 Cr
₹4 Cr₹2 Cr₹2 Cr₹0
₹80 Cr₹12 Cr₹36 Cr₹26 Cr
₹11 Cr₹2 Cr₹3 Cr₹0
-₹8 Cr-₹52 L-₹65 L₹13 L
₹265 Cr₹0₹0₹0
₹75 L₹50 L₹21 L₹8 L
₹348 Cr₹14 Cr₹38 Cr₹26 Cr
————
₹149 Cr₹58 Cr₹53 Cr₹22 Cr
₹165 Cr₹17 Cr₹17 Cr₹13 Cr
₹223 Cr₹73 Cr₹71 Cr₹35 Cr
₹36 Cr₹14 Cr₹12 Cr₹7 Cr
₹573 Cr₹162 Cr₹153 Cr₹77 Cr
₹1416 Cr₹272 Cr₹267 Cr₹134 Cr
₹6 Cr₹2 Cr₹4 Cr₹2 Cr
₹319 Cr₹94 Cr₹119 Cr₹69 Cr
————
₹432 Cr₹79 Cr₹99 Cr₹55 Cr
₹68 Cr₹26 Cr₹29 Cr₹11 Cr
₹364 Cr₹53 Cr₹70 Cr₹44 Cr
₹212 Cr₹50 L₹0₹2 Cr
₹16 Cr₹17 Cr₹9 Cr₹5 Cr
₹2 Cr₹1 Cr₹61 L₹92 L
₹594 Cr₹72 Cr₹80 Cr₹52 Cr
————
₹172 Cr₹51 Cr₹37 Cr₹13 Cr
₹181 Cr₹127 Cr₹127 Cr₹61 Cr
₹417 Cr₹2 Cr₹4 Cr₹17 L
₹18 Cr₹4 Cr₹2 Cr₹87 L
₹34 Cr₹16 Cr₹16 Cr₹7 Cr
₹822 Cr₹200 Cr₹187 Cr₹82 Cr
₹249 Cr₹38 Cr₹35 Cr₹5 Cr
₹1416 Cr₹272 Cr₹267 Cr₹134 Cr
₹111₹35₹56₹44
₹111₹35₹28₹22

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023
₹12 Cr₹20 Cr₹13 Cr₹7 Cr
₹31 Cr₹20 Cr₹21 Cr₹12 Cr
₹56 Cr-₹7 Cr-₹63 Cr-₹29 Cr
₹98 Cr₹34 Cr-₹30 Cr-₹10 Cr
₹93 Cr₹33 Cr-₹30 Cr-₹13 Cr
-₹274 Cr₹44 L-₹46 Cr-₹19 Cr
₹596 Cr-₹36 Cr₹79 Cr₹24 Cr
₹415 Cr-₹2 Cr₹2 Cr-₹8 Cr
₹2 Cr₹4 Cr₹2 Cr₹10 Cr
₹417 Cr₹2 Cr₹4 Cr₹2 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)481.05
Volume (₹)2.08 L
High (₹)494.90
Upper Circuit576.80
Low (₹)462.80
Lower Circuit384.60
Prev Close480.70
52W High (₹)706.00
Price469.25
52W Low (₹)400.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)2123.47 Cr
Div. Yield (%)0.00
PE Ratio128.66
Debt to Equity0.65
Price to Book0.00
Book Value111.09
EPS (TTM)3.74
Face Value5.00
ROE (%)4.88

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
SAIPARENTNSE
LTP
1W Low
1W High
Market cap (₹)
1769.9-7.8 (-0.44%)
1722
1855
4,24,202Cr
10064+284 (2.90%)
9621.50
10064
2,64,141Cr
4650+36.6 (0.79%)
4532
4675
1,74,402Cr
2323-82.5 (-3.43%)
2206.10
2441.90
1,26,811Cr
1240.6-4.9 (-0.39%)
1182
1254.20
1,23,685Cr
1368.3+16.3 (1.21%)
1336.70
1368.30
1,11,868Cr
1396.9+18 (1.31%)
1357
1396.90
1,11,650Cr
2475-17.8 (-0.71%)
2457.90
2528
1,02,196Cr
1694.5+13.1 (0.78%)
1647.20
1697.40
96,951Cr
2015.9+4.9 (0.24%)
1974
2033.80
91,301Cr
469.25-52.7 (-10.10%)
462.80
536.95
2,123Cr

Sai Parenteral's Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹27.26Cr; with other income of ₹3.74Cr, profit before interest and tax came to ₹19.15Cr. Interest expense was ₹9.36Cr; PBT before exceptional items stood at ₹9.79Cr. Cost mix (full year): raw materials ₹238.11Cr; employee cost ₹29.28Cr; depreciation ₹8.11Cr; other expenses ₹155.15Cr. Basis: consolidated annual results.

Sai Parenteral's Ltd Quaterly Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹27.26Cr; with other income of ₹3.74Cr, profit before interest and tax came to ₹19.15Cr. Interest expense was ₹9.36Cr, taking profit before tax to ₹9.79Cr.